Format

Send to

Choose Destination
Am J Infect Control. 2018 Mar;46(3):322-327. doi: 10.1016/j.ajic.2017.09.005. Epub 2017 Oct 16.

The epidemiology of nonventilator hospital-acquired pneumonia in the United States.

Author information

1
Northeastern University, Boston, MA; Department of Nursing, Hallmark Health, Medford, MA; Sage Products, Stryker Medical, Cary, IL. Electronic address: kkgiuliano96@gmail.com.
2
School of Nursing, California State University, Sacramento, CA.
3
Department of Nursing, Sutter Medical Center, Sacramento, CA.

Abstract

BACKGROUND:

Nonventilator hospital-acquired pneumonia (NV-HAP) is among the most common hospital-acquired infections. The purpose of our study was to quantify the incidence and influence of NV-HAP in the United States using a national dataset.

METHODS:

The 2012 US National Inpatient Sample dataset was used to compare an NV-HAP group to 4 additional group cohorts: pneumonia on admission, general hospital admissions, matched on mortality and disease severity, and ventilator-associated pneumonia (VAP). The main outcome was NV-HAP incidence. The secondary outcome was to compare hospital length of stay, total hospital charges, and mortality between the NV-HAP group and the 4 additional group cohorts.

RESULTS:

The overall incidence of NV-HAP was 1.6%, which represents a rate of 3.63 per 1,000 patient-days. NV-HAP was associated with increased total hospital charges, a longer hospital length of stay, and greater likelihood of death in comparison to all groups except patients with VAP.

CONCLUSION:

NV-HAP is an underappreciated and serious patient safety issue, resulting in significant increases in cost, length of stay, and mortality. Efforts toward prevention of NV-HAP should be raised to the same level of concern as VAP prevention.

KEYWORDS:

Hospital cost; Mortality; VAP

PMID:
29050905
DOI:
10.1016/j.ajic.2017.09.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center